ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1080

Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience

Cristiano S. Moura 1, Denis Choquette 2, Louis Coupal 3, Louis Bessette 4 and Sasha Bernatsky5, 1McGill University Health Centre, Montreal, QC, Canada, 2Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, 3Institut de Recherche en Rhumatologie de Montréal, Montreal, QC, Canada, 4Laval University, Quebec City, QC, Canada, 5Research Institute of the McGill University Health Centre, Montreal, QC, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: etanercept and biosimilars

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Biosimilars hold the potential to improve access to needed therapies at a reduced cost. In Canada, biosimilar etanercept (bsETA-Brenzys® and Erelzi®) were recently approved for rheumatoid arthritis (RA) and other rheumatologic conditions; however, comparisons of patterns of use of biosimilar with its originator product (boETA-Enbrel®) are scarce. Our objective was to describe the recent use of bsETA and boETA in patients with RA, ankylosing spondylitis (AS), and psoriatic arthritis (PsA).

Methods: Data from patients initiating bsETA (either biologic-naïve users, patient transitioning from boETA, swappers and switchers from other biologic agents) were extracted from RHUMADATA®, a practice-based registry (14 Quebec rheumatologists) for the period of January 2015 to November 2018. For comparison purposes, we identified patients initiating/switching/swapping to the boETA product in the same period. We obtained baseline demographics and clinical data for all patients. Therapy persistence in bsETA versus boETA initiators was compared using Kaplan-Meier methods and adjusted hazard ratios (HR). Our hazard models adjusted for age, sex, disease duration, methotrexate (MTX) dose at baseline, and comorbidities (Charlson comorbidity index)

Results: We studied 48 patients initiating bsETA (including 37 etanercept-naïve patients) and 59 patients initiating boETA. Sex distribution, age, comorbidities and disease duration (at etanercept initiation) were similar between groups (Table 1). Use of MTX and/or other conventional synthetic DMARD (csDMARDs) at etanercept initiation was also similar between groups; however, patients in the boETA group started with a significant higher dose of MTX (22.0 ± 3.5mg) when compared to bsETA users (19.0 ± 5.2mg, p=0.011). Persistence on therapy was similar in both groups (Figure 1): after 12 months, 75% of originator etanercept versus 84% of biosimilar etanercept initiators remained on their initial treatment. Adjusting for baseline age, sex, disease duration, methotrexate dose at baseline, and comorbidities, the adjusted HR for therapy persistence in biosimilar etanercept versus originator etanercept group was 2.05 (95% CI 0.83, 5.04).

Conclusion: Patients initiating bsETA or boETA were similar in terms of age, disease duration, disease activity, and comorbidities. We were unable to identify clear differences in treatment persistence between the two groups; a strong trend for greater persistence with biosimilar versus originator may be related to residual confounding (e.g.: disease activity). Further work is ongoing to study outcomes in a larger, multicentre group of patients.


Table1_ACREtanercept

Table 1 – Baseline characteristics according to the initial treatment.


Figure1_ACREtanercept

Figure 1 – Kaplan Meier survival curves for therapy persistence per treatment group of a- boETA, and b bsETA.


Disclosure: C. Moura, None; D. Choquette, AbbVie, 5, 8, AbbVie Canada, 5, 8, 9, Amgen, 5, 8, Amgen Canada, 5, 8, 9, BMS, 5, 8, BMS Canada, 5, 8, 9, Celgene, 5, 8, Celgene Canada, 5, 8, 9, Eli Lilly Canada, 5, 8, 9, Eli-Lilly, 5, 8, Merck, 5, 8, Merck Canada, 5, 8, 9, Novartis, 5, 8, Novartis Canada, 5, 8, 9, Pfizer, 5, 8, Pfizer Canada, 5, 8, 9, Sandoz Canada, 5, 8, 9, Sanofi-Genzime, 5, 8, Sanofi-Genzyme, 5, 8, 9; L. Coupal, None; L. Bessette, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Amgen, 2, 5, 8, Amgen, BMS, Janssen, Roche, UCB Pharma, AbbVie Inc, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, and Novartis., 2, 5, 8, BMS, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Bristol-Myers-Squibb, 2, 5, 8, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Janssen, 2, 5, 8, Lilly, 2, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8, UCB Pharma, 2, 5; S. Bernatsky, None.

To cite this abstract in AMA style:

Moura C, Choquette D, Coupal L, Bessette L, Bernatsky S. Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/biosimilar-etanercept-use-in-rheumatoid-arthritis-ankylosing-spondylitis-and-psoriatic-arthritis-the-rhumadata-registry-experience/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biosimilar-etanercept-use-in-rheumatoid-arthritis-ankylosing-spondylitis-and-psoriatic-arthritis-the-rhumadata-registry-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.